Mission
Japan has a high level of global competitiveness in life sciences fostered by sustained efforts and innovation breakthroughs that many researchers in academia, research institutions, and pharmaceutical companies are bringing forward. Our mission is to help such research outcomes to be funded and to catalyze the translation of innovative medicines serving the needs of the patients.

About us
Fund: New Life Science I Investment Limited Partnership
Founded: February 7, 2019
Fund Size: JPY 10.1 billion yen (Final close at February 6, 2020)
GP: New Life Science I LLP
Target: Biotech
Stage: Company Creation, Seed, Early, Middle, Later
Company: Shinsei Capital Partners, Ltd.
Management: CEO Manabu Nakamura
Director Yoshiyuki Yamakawa (Chairman, HIBIKI Partners)
Director Nobuyuki Hata (Professor, Graduate Institute for Entrepreneurial Studies)
Director Takahisa Komoda (Senior Managing Executive Officer, SBI Shinsei Bank)
Auditor Fuyuki Kojima (Partner attorney, HIFUMI Law)
History
July 2004 Shinsei
Bank (current SBI Shinsei Bank) started Pre-IPO investment
in Private Equity division
Invested in 75 companies over 14 years from 2004 to 2018, and 26 listed
February 2019 Established Shinsei Capital Partners as a carve-out of Life ScienceInvestment Team in Shinsei Corporate Investment